Local Institution - 0054
Athens, Attikí, Greece
7 recruiting
Showing 1–12 of 12 trials
Recruiting
Phase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company472 enrolledNCT07686263
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled65 locationsNCT07175285
Recruiting
Phase 3
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
SchizophreniaAutism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company400 enrolled95 locationsNCT07424404
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb500 enrolled186 locationsNCT07100080
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Bristol-Myers Squibb1,500 enrolled52 locationsNCT07379827
Recruiting
Phase 2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Solid Tumors
Mirati Therapeutics Inc.170 enrolled101 locationsNCT07415031
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Schizophrenia
Bristol-Myers Squibb250 enrolled56 locationsNCT06882785
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled22 locationsNCT06947941
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bipolar DisorderMania
Bristol-Myers Squibb424 enrolled104 locationsNCT07140913
Recruiting
Phase 1
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502